(Q37635370)

21 August 2017

1 reference

title

Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals (English)

1 reference

post-exposure prophylaxis

21 August 2017

0 references

1 reference

based on heuristic

inferred from title

author

Charles Edward Rupprecht

1

object named as

Charles E Rupprecht

1 reference

21 August 2017

10

William Schaffner

1 reference

21 August 2017

9

Martin I Meltzer

1 reference

21 August 2017

2

Deborah Briggs

1 reference

21 August 2017

11

Paul R Cieslak

1 reference

21 August 2017

Catherine M Brown

3

1 reference

21 August 2017

Richard Franka

4

1 reference

21 August 2017

Samuel L Katz

5

1 reference

21 August 2017

Harry D Kerr

6

1 reference

21 August 2017

Susan Lett

7

1 reference

21 August 2017

Robin Levis

8

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

21 August 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

21 August 2017

volume

27

1 reference

21 August 2017

issue

51

1 reference

21 August 2017

page(s)

7141-7148

1 reference

Causes, costs, and estimates of rabies postexposure prophylaxis treatments in the United States.

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

The role of immune responses in the pathogenesis of rabies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Acute rabies death mediated by antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Management of rabies in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Investigation of the role of healthy dogs as potential carriers of rabies virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Epidemiology of human rabies in the United States, 1980 to 1996.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

An evaluation of second generation tissue culture rabies vaccines for use in man: a four-vaccine comparative immunogenicity study using a pre-exposure vaccination schedule and an abbreviated 2-1-1 postexposure schedule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Interaction of rabies vaccine with human rabies immunoglobulin and reliability of a 2-1-1 schedule application for postexposure treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

One-year study of the 2-1-1 intramuscular postexposure rabies vaccine regimen in 100 severely exposed Thai patients using rabies immune globulin and Vero cell rabies vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Persistence of humoral immunity to rabies 1100 days after immunization and effect of a single booster dose of rabies vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Rabipur: a reliable vaccine for rabies protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Successful protection of humans exposed to rabies infection. Postexposure treatment with the new human diploid cell rabies vaccine and antirabies serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Immunization against rabies with rabies immune globulin, human (RIGH) and a human diploid cell strain (HDCS) rabies vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Intravenous human rabies immunoglobulin for post-exposure prophylaxis: serum rabies neutralizing antibody concentrations and side-effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Rabies neutralizing antibody in serum of children compared to adults following post-exposure prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Evaluation of the safety and immunogenicity of a new, heat-treated human rabies immune globulin using a sham, post-exposure prophylaxis of rabies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Immunogenicity, safety and lot consistency in adults of a chromatographically purified Vero-cell rabies vaccine: a randomized, double-blind trial with human diploid cell rabies vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Assessing the relationship between antigenicity and immunogenicity of human rabies vaccines. Results of a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Longevity of rabies antibody titre in recipients of human diploid cell rabies vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Long-term humoral and cellular immunity after vaccination with cell culture rabies vaccines in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Duration of immunity: an anamnestic response 14 years after rabies vaccination with purified chick embryo cell rabies vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Immune response to rabies booster vaccination in subjects who had postexposure treatment more than 5 years previously

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Survival of neutralizing antibody in previously rabies vaccinated subjects: a prospective study showing long lasting immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Long-term anti-rabies antibody persistence following intramuscular or low-dose intradermal vaccination of young Vietnamese children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Animal models in the pathogenesis and treatment of rabies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Postexposure prophylaxis for prevention of rabies in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

The incurable wound revisited: progress in human rabies prevention?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Rabies virus pathogenesis in relationship to intervention with inactivated and attenuated rabies vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Failure of postexposure treatment of rabies in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Immunogenicity of purified vero cell rabies vaccine used in the treatment of fox-bite victims in India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Failures of post-exposure rabies prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Assessing the burden of human rabies in India: results of a national multi-center epidemiological survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Rabies exposures, post-exposure prophylaxis and deaths in a region of endemic canine rabies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Cost effectiveness of rabies post exposure prophylaxis in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Rabies postexposure prophylaxis, New York, 1995-2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Direct and indirect costs of rabies exposure: a retrospective study in southern California (1998-2002).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Failure of multiple-site intradermal postexposure rabies vaccination in patients with human immunodeficiency virus with low CD4+ T lymphocyte counts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

Failure of pre- and postexposure rabies vaccinations in a child infected with HIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.029

10.1016/J.VACCINE.2009.09.029

7 January 2021

Identifiers

DOI

1 reference

21 August 2017

1 reference